The Phase 2b, multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial is designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to preserve muscle and augment fat loss in approximately 150 patients with sarcopenic obesity or overweight elderly (>60 years of age) patients receiving semaglutide (Wegovy®). The primary endpoint is total lean body mass, and the key secondary endpoints are total body fat mass and physical function as ...

About the Enobosarm Phase 2b clinical trial About Enobosarm Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 ENABLAR-2 clinical trial of * Wegovy® is a r ...

Investor and Media Contact: About Sarcopenic Obesity According to the CDC, 41.5% of older adults have obesity in the United States and could benefit from a weight loss medication. Up to 34.4% of these obese patients over the age of 60 have sarcopenic obesity. This large subpopulation of sarcopenic obese patients is especially at risk for taking GLP-1 drugs for weight loss as they already have critically low amount of muscle due to age-related muscle loss. Further loss of muscle mass when taking a GLP-1 RA m ...

Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Officer Michele Greco - Chief Financial Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Dennis Ding - Jefferies William Wood - B. Riley Securities Rohan Mathur - Oppenheimer Operator Good morning ladies and gentlemen and welcome to Veru Inc.'s Investors Conference Call. [Operator Instruc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127 (Address of Principal Executive Offices) (Zip Code) 305-509-6897 (Registrant's Telephone Number, Including Area Code) N/A (Mark One) Commission File Number 1-13602 | | | (Exact Name of Registrant as Specified in its Charter) Wisconsin 39-1144397 As of May 6, 2024, the registrant had 146,383,920 shares of $0.01 par value common stock outstanding. (Former Name, Former Address and ...

Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program —Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling— High Quality Weight Loss Program Update: The Company's high quality weight loss program is f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number 1-13602 | | | (Exact Name of Registrant as Specified in its Charter) Wisconsin 39-1144397 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127 (Address of Principal Executive Offices) (Zip Code) 305-509-6897 (Registrant's Telephone Number, Including Area Code) N/A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number 1-13602 Veru Inc. (Name of registrant as specified in its charter) | Wisconsin 39-1144397 | | | --- | --- | | (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) | | | 2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127 | | | (Address of principal executive offices) (Zip Code) | | | Registrant's telephone number, including area code (305) 509-6897 | | | ...

Veru Inc. (NASDAQ:VERU) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - Chief Financial Officer & Chief Accounting Officer Dr. Gary Barnett - Chief Scientific Officer Michael Purvis - Executive Vice President, General Counsel and Corporate Strategy Conference Call Participants Operator Good morning, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number 1-13602 | | | (Exact Name of Registrant as Specified in its Charter) Wisconsin 39-1144397 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127 N/A (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | ...